METHODS.
The consequence of interaction between stromal cells and tumor cells with respect to tumor cells' response to three anti-tumor drugs (COL-3, doxorubicin, and taxol) was investigated in three established prostate cancer (CaP) cell lines (LNCaP, DU 145 and PC-3). Modulation of drug-induced cytotoxicity and apoptosis in CaP cells by purified cytokines and stromal cell-conditioned media (SCM) were investigated. Conditioned media were prepared from primary fibroblasts and microvessel endothelial cells (EC) cultures of human skin, lung and prostate. Conditioned media and co-cultures of rat bone-marrow fibroblasts and mouse 3T3 fibroblasts cultures were also tested. Cytotoxicity was quantified by Thiazolyl blue (MTT) reduction assay or inhibition of [ 3 H]-methyl thymidine incorporation. Histone -1 released due to apoptotic activity was measured using the Celldeath-ELISA-Plus kits (Roche, NJ). Levels of cytokines in various treatment groups were quantified using commercial ELISA-kits. Modulation of IL-1$ and IL-6 mRNA in tumor cells by SCM and cytokines were compared using a semi-quantitative RT-PCR [3] .
RESULTS. SCM derived from primary and established fibroblast cultures of skin, lung, bone marrow and prostate origin were able to reduce or increase drug-induced cytotoxicity in all the three CaP cell lines. Mouse 3T3 fibroblast CM and human skin and prostate-derived SCM increased cytotoxicity of anticancer drugs by 20-80%, compared to regular complete culture medium. Cytotoxicity of taxol was least affected compared to COL-3 (a chemically modified non-antimicrobial tetracycline with potent anti-tumor activity [4] . (Cytotoxicity due to doxorubicin was affected moderately by SCM or cytokines. Human lung and bone marrowderived SCM reduced drug-induced cytotoxicity by 1.5 to 3-folds. Cytotoxicity and druginduced apoptosis was higher in the presence of 3T3 cells, human lung and skin fibroblast cocultures but was unaffected in prostate stromal cells and microvessel endothelial cells. These SCMs were able to induce IL-6 and IL-1$ in tumor cells, that was partially inhibited by neutralizing anti-IL-6 and anti-IL-1$ antibodies. However, the inhibition was modest. Furthermore, IL-6 and Il-1$ levels were elevated in CaP cell conditioned medium when treated with drugs, but was increased further, up to 5-fold, in the presence of SCMs. Expression of cytokine-specific mRNA was significantly elevated in the presence of SCM. In all cases, as revealed by a semi-quantitative RT-PCR, the SCM that sensitized tumor cells to drugs increased IL-6 mRNA in tumor cells (DU145 and PC-3) (Fig. 1) . Anti-IL-6 antibody could only partially (#50%) reverse SCM-induced drug sensitivity, indicating other factors (being identified by gene expression array analysis) may also be responsible for modulation of cytotoxicity. Similar activity was observed in the case of IL-1$ expression in the presence of anti-cancer drug (e.g., taxol) and SCM (Fig. 2) . A significant increase in cytotoxicity and druginduced apoptosis with a concomitant increase in IL-6 and IL-1$ mRNA transcripts was observed in CaP cells exposed to drugs in the presence of skin fibroblasts, microvessel endothelial cell conditioned medium (Fig. 2) .
CONCLUSIONS.
These results indicate that the effect of anticancer drugs can be significantly altered by stromal-derived factors that act by inducing IL-6 and IL-I$ in tumor cells, which may trigger additional pathways of drug-induced cytotoxicity and apoptosis. Further understanding of the mechanism and impact of organ-specific stromal factors should be able to reduce the failure of chemotherapy in metastatic malignancy. [Work supported by PHS (NCI) R01-CA 61038 and DoD/ US Army DAMD17-98-18526 grants.]
